Clinical trial · no report yet · Phase 2

PICS

Evaluation of the Efficacy and Safety of Interleucin-2 Combined With PD-1 Monoclonal Antibody and CAPOX in Preoperative Neoadjuvant Therapy for Mid-low Locally Advanced Rectal Cancer - a Single-center, Single-arm, Open-label Clinical Trail

NCT06108596 ↗
Completed
The First Affiliated Hospital with Nanjing Medical University
Focused

We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.

Preliminary discovery

Commentary in our index that names this trial so far

Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.

Channel	Found
Bluesky threads	4
X threads	1

The trial

ClinicalTrials.gov

Official title: Evaluation of the Efficacy and Safety of Interleucin-2 Combined With PD-1 Monoclonal Antibody and CAPOX in Preoperative Neoadjuvant Therapy for Mid-low Locally Advanced Rectal Cancer
Phase: Phase 2
Status: Completed
Conditions: Locally Advanced Rectal Adenocarcinoma
Interventions: Sintilimab with Interleukin-2+CAPOX
Arms: Experimental group · Experimental
Enrollment: 33
Primary outcomes: pCR
Sponsor: The First Affiliated Hospital with Nanjing Medical University
Start: Oct 21, 2023
Primary completion: Dec 31, 2024
Results posted: No
Registry record: NCT06108596 · updated Jan 21, 2025

Publications

linked from the registry

Tang J, Wang L, Yang S, Peng W, Zhang Y, Zhang Y, Jin K, Wang X, Feng Y, Sun Y. Total neoadjuvant chemotherapy combined with PD-1 blockade and IL-2 in MSS/pMMR locally advanced rectal cancer: short-term results of a prospective, single-arm phase II study. Signal Transduct Target Ther. 2026 May 4;11(1):163. doi: 10.1038/s41392-026-02683-8. PubMed 42071008